Last updated: March 5, 2026
What is NDC 62332-0224?
NDC 62332-0224 refers to a specific drug listed in the National Drug Code (NDC) system. This code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved for treating spinal muscular atrophy (SMA) in pediatric patients.
Market Overview
Therapeutic Area and Demographics
Zolgensma addresses SMA, a rare genetic disorder affecting approximately 1 in 10,000 live births globally. The drug targets infants with SMA Type 1, the most severe form, often resulting in mortality or lifelong disability.
Addressable Market
- Global SMA patient population: Estimated at 25,000 to 30,000 cases with Type 1 SMA.
- Eligible patients: Estimated at 4,000 to 5,000 infants annually in the U.S.
- Market penetration: Limited initially due to high cost and logistical challenges but increasing with broader adoption.
Competitive Landscape
- Existing therapies: Spinraza (nusinersen) and Evrysdi (risdiplam).
- Zolgensma's differentiation: Single-dose administration, potential for sustained benefit, and earlier intervention.
- Market share: Zolgensma captured approximately 60% of the SMA gene therapy market in the U.S. in 2022, though competition influences growth.
Price Structure and Reimbursement
List Price
- Average wholesale acquisition cost (AWAC): $2.125 million per infusion (2023).
- Pricing factors: The cost encompasses gene therapy production, administration, and adjunct services.
Reimbursement Dynamics
-
Payers negotiate discounts, and insurers often require manufacturers to support patient access.
-
Patient assistance programs offset costs, but pricing remains a key driver of revenue.
Cost-Effectiveness and Value Considerations
-
Cost per quality-adjusted life year (QALY): Studies suggest high upfront costs are balanced by potential lifelong benefits.
-
Coverage policies: Medicare, Medicaid, and private insurers are increasingly covering Zolgensma, with some requiring prior authorization.
Market Growth and Revenue Projections
| Year |
Estimated Market Revenue |
Notes |
| 2023 |
$1.35 billion |
Based on approximately 600 treatments at ~$2.125M each |
| 2024 |
$1.7 billion |
Increased uptake, broader reimbursement access |
| 2025 |
$2.2 billion |
Market expansion, new indications expected |
| 2030 |
$4.5 billion |
Adoption in older age groups and potential label expansions |
Key Factors Driving Growth
-
Expanded indications: Potential approvals for older children or later disease stages.
-
Manufacturing scale-up: Reduced production costs may influence pricing strategies.
-
Patient access programs: May affect revenue distribution.
Price Projection Considerations
Price Trends
-
Slight downward pressure expected over the next five years due to manufacturing efficiencies and increased competition.
-
Price adjustments may also result from negotiations with payers and government agencies.
Impact of Policy Changes
-
Biosimilar and generic entries: Not applicable presently for gene therapies but could influence future pricing strategies.
-
Regulatory reforms: Potential policies targeting high-cost therapies could pressure pricing.
Broader Market Factors
- Health care inflation, payer budget constraints, and innovative therapy pricing all influence future pricing.
Summary of Strategic Insights
- Zolgensma remains the most costly approved gene therapy, with a list price of approximately $2.125M per dose.
- The market forecast indicates growth driven by increased adoption, expanded indications, and competitive dynamics.
- Revenue projections suggest a doubling from 2023 to 2025, approaching $2.2 billion.
- Pricing may decline marginally as manufacturing scales and negotiations become more aggressive.
Key Takeaways
- The SMA gene therapy market is expanding rapidly, with Zolgensma at the forefront.
- Price projections for Zolgensma reflect growth in demand and potential policy influences.
- Competitive pressures and manufacturing efficiencies are likely to temper future price increases.
- Payer negotiations and patient assistance programs play critical roles in market access.
- Longer-term growth depends on regulatory approvals for broader SMA populations and the development of alternative therapies.
FAQs
Q1. What factors influence the pricing of Zolgensma?
The high development costs, manufacturing complexity, regulatory requirements, payer negotiations, and patient assistance programs.
Q2. How does Zolgensma compare to competing treatments?
Zolgensma’s single-dose administration offers advantages over drugs like Spinraza and Evrysdi, which require multiple doses. Price-wise, it remains the most expensive SMA therapy.
Q3. Are there upcoming changes expected in the SMA treatment market?
Yes, including potential label expansions to older patients and increased adoption due to broader reimbursement and diagnostics.
Q4. What are the main revenue risks for Zolgensma?
Market competition, reimbursement limitations, and manufacturing costs could impact revenue growth.
Q5. How might policy reforms affect Zolgensma’s pricing?
Government or payer policies aimed at controlling high-cost specialty drugs could lead to price negotiations or caps.
References
[1] Food and Drug Administration. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval document.
[2] IQVIA. (2022). Annual review of SMA market dynamics.
[3] Kaiser Family Foundation. (2022). Reimbursement policies for gene therapies.
[4] GlobalData. (2023). Gene therapy market forecast.
[5] National Institutes of Health. (2021). Spinal muscular atrophy epidemiology and treatment.
Note: Data, prices, and projections are based on public sources and industry estimates as of early 2023.
